Reporter @nytimes on mainly #covid19 Winner 2019 Victor Cohn Prize. Before: Founding EIC @Spectrum, co-founder @CultureDish Apoorva@NYTimes.com
NEW: The J&J coronavirus vaccine is much less effective against Delta and Lambda variants than against the original virus, acc to a new study -- suggesting the 13 mil people who got it should get a second dose, ideally one of the mRNA vaccines.
“People who were inoculated with the J.&J. vaccine “are relying on that primary response to maintain high levels of antibodies, which is difficult, especially against the variants,” she said.” @VirusesImmunity twitter.com/apoorva_nyc/st…
I struggle when I see this sort of thing. Maybe it's right, but we don't know yet.
Making a medical recommendation—contra CDC etc.—is unwarranted.
1. The study is a non-peer reviewed preprint.
2. It's conducted using pseudovirus, not actual virus... twitter.com/apoorva_nyc/st…
3. Critically the study looks at neutralizing antibody levels not vaccine effectiveness. Direct extrapolation seems foolhardy.
4. For example, we *know* from the original J&J trial that it works at low neutralizing antibody titres against Beta. Why might it not be same w/ Delta?
For months I have been advocating for CDC and FDA to issue guidance on second doses for the millions of people who got the single dose J&J vaccine.
Now we have more data. I urge them to act. The delta variant doesn't respect one dose. nytimes.com/2021/07/20/hea…
Epidemiologist & health economist. Senior Fellow, @FAScientists. Former 16 yrs @Harvard. Environment, health & social justice. COVID updates since Jan 2020.
📍J&J Vaccine May Be Less Effective Against Delta, Study Suggests. Many who received the shot may need to consider boosters, the authors said. FDA & CDC not recommending 2nd shot—yet. @VincentRK and I warned for months about 1-shot J&J not enough.
2) The coronavirus vaccine made by Johnson & Johnson is much less effective against the Delta and Lambda variants than against the original virus, according to a new study posted online on Tuesday. biorxiv.org/content/10.110…
4) But the conclusions add to evidence that the 13 million people inoculated with the J.&J. vaccine may need to receive a second dose — ideally of one of the mRNA vaccines made by Pfizer-BioNTech or Moderna, the authors said.
5) The conclusions are at odds with those from smaller studies published by Johnson & Johnson earlier this month suggesting that a single dose of the vaccine is effective against the variant even eight months after inoculation.
6) The new study has not yet been peer reviewed nor published in a scientific journal. But it is consistent with observations that a single dose of the AstraZeneca —which has a similar architecture to the J.&J. vaccine — shows only 33% efficacy against symptomatic Delta variant.